| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.0065 | 0.9 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | Genentech Cpd 10 | GDSC1000 | pan-cancer | AAC | -0.0054 | 0.9 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.028 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.0064 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | -0.0051 | 0.9 |
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.0086 | 0.9 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.0053 | 0.9 |